CJC-1295 / Ipamorelin
The classic GH-support pairing — a GHRH analog and a selective secretagogue in one combined vial.
CJC-1295 / Ipamorelin combines a GHRH analog (CJC-1295) with a selective ghrelin-receptor agonist (Ipamorelin). The two stimulate growth-hormone release through complementary pathways, which is why they’re so often prescribed together.
Prescription required. Final clinical decisions rest with the prescribing physician.
What is CJC-1295 / Ipamorelin?
This blend pairs CJC-1295 (a GHRH analog) with Ipamorelin (a selective ghrelin-receptor agonist). Because they act on different receptors, combining them can produce a stronger, more sustained GH pulse than either peptide alone — while Ipamorelin’s selectivity keeps cortisol and prolactin largely unaffected.
It’s one of the most commonly prescribed recovery stacks. The blend is accessed through licensed compounding pharmacies under physician prescription; it is not an FDA-approved finished product.
Potential benefits
Complementary GH release
Two pathways — GHRH + ghrelin-receptor — for amplified, sustained GH pulses.
Convenient single vial
Both peptides combined in one formulation, one injection.
Recovery & body composition
A go-to stack for recovery and lean-mass support.
Selective profile
Ipamorelin’s selectivity limits effects on cortisol and prolactin.
How it works
How it’s taken
A single subcutaneous injection of the combined formulation, typically at night and/or post-exercise per physician protocol.
Typical protocol
Run in cycles with periodic reassessment; the physician sets the ratio, dose, and timing.
How ordering works
Complete the intake
Share your goals, health history, and current medications — about 5 minutes.
Physician evaluation
An independent, board-certified physician reviews your intake and, if appropriate, prescribes CJC-1295 / Ipamorelin with a dosing protocol.
Compounded & shipped
The prescription is filled by a licensed compounding pharmacy and shipped to your door with instructions.
What to know before CJC-1295 / Ipamorelin
CJC-1295 / Ipamorelin is a bioactive compound. The physician you’re connected with will review the relevant risks and contraindications for your situation before prescribing.
- •Injection-site reactions are the most common side effect.
- •May cause mild water retention, flushing, or head-rush after dosing.
- •Active cancer or recent malignancy is a contraindication for GH-stimulating peptides.
- •Pregnancy and breastfeeding are contraindications for most peptides.
- •Source matters: gray-market “research only” peptides skip physician oversight and quality testing. FirstCall connects you with a licensed physician and a compounding pharmacy that follows USP standards.
CJC-1295 / Ipamorelin FAQ
Why combine CJC-1295 and Ipamorelin?
They stimulate GH through complementary pathways, so together they can produce a stronger, more sustained release than either alone — with Ipamorelin’s selectivity limiting cortisol/prolactin effects.
Is this blend FDA-approved?
No. It is prepared by licensed compounding pharmacies and prescribed off-label; it is not an FDA-approved finished drug product.
How is it taken?
One subcutaneous injection of the combined vial; the physician you’re connected with sets the dose and timing.
Is it better than either peptide alone?
Many clinicians prefer the combination for a more complete GH response, but the right choice depends on your goals — the physician will advise.
How much does it cost?
The CJC-1295 / Ipamorelin blend starts from $199/month. Final pricing is confirmed by the compounding pharmacy after your physician evaluation. The initial evaluation is free.
Ready to start CJC-1295 / Ipamorelin?
Complete a short medical intake — a supervising physician reviews it and, if appropriate, writes your prescription, and a licensed pharmacy ships to your door.
Pricing & regulatory note: The $199/mo price is an indicative starting point confirmed by the compounding pharmacy after physician evaluation. CJC-1295 / Ipamorelin is not an FDA-approved finished drug product; it is prepared by licensed compounding pharmacies and prescribed off-label. FDA guidance on peptide compounding continues to evolve and availability can change. A prescription is required.